Conditioning regimens in allo-SCT for thalassemia major

Bone Marrow Transplantation

Volumn 49, Issue 5, 2014, Pages 607-610

  Mathews, V ^a   Savani, B N ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

conditioning regimen; regimen related toxicity; thalassemia major

Indexed keywords

AZATHIOPRINE; BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; HYDROXYUREA; TREOSULFAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; EVENT FREE SURVIVAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LIVER VENOOCCLUSIVE DISEASE; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; THALASSEMIA MAJOR; TREATMENT OUTCOME; ALLOTRANSPLANTATION; BETA-THALASSEMIA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PROCEDURES;

BETA-THALASSEMIA; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84900345329     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.216     Document Type: Review

References (33)

1. Thomas ED, Buckner CD, Sanders JE, Papayannopoulou T, Borgna-Pignatti C, De Stefano P et al. Marrow transplantation for thalassaemia. Lancet 1982; 2: 227-229
2. Lucarelli G, Polchi P, Galimberti M, Izzi T, Delfini C, Manna M et al. Marrow transplantation for thalassaemia following busulphan and cyclophosphamide. Lancet 1985; 1: 1355-1357
3. Bhatia M, Walters MC. Hematopoietic cell transplantation for thalassemia and sickle cell disease: Past, present and future. Bone Marrow Transplant 2008; 41: 109-117
4. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417-421
5. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Durazzi SM et al. Bone marrow transplantation in adult thalassemia. Blood 1992; 80: 1603-1607
6. Mathews V, George B, Deotare U, Lakshmi KM, Viswabandya A, Daniel D et al. A new stratification strategy that identifies a subset of class III patients with an adverse prognosis among children with beta thalassemia major undergoing a matched related allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 889-894
7. Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U et al. Outcomes of transplantation with related- And unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant 2006; 12: 683-687
8. Fang JP, Xu LH. Hematopoietic stem cell transplantation for children with thalassemia major in China. Pediatr Blood Cancer 2010; 55: 1062-1065
9. Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK et al. HLA-matched sibling bone marrow transplantation for beta-Thalassemia major. Blood 2010; 117: 1745-1750
10. Chiesa R, Cappelli B, Crocchiolo R, Frugnoli I, Biral E, Noe A et al. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: Limited toxicity with a dose-Adjustment policy. Biol Blood Marrow Transplant 2010; 16: 622-628
11. Lawson SE, Roberts IA, Amrolia P, Dokal I, Szydlo R, Darbyshire PJ. Bone marrow transplantation for beta-Thalassaemia major: The UK experience in two paediatric centres. Br J Haematol 2003; 120: 289-295
12. Sodani P, Gaziev D, Polchi P, Erer B, Giardini C, Angelucci E et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years. Blood 2004; 104: 1201-1203
13. Lucarelli G, Clift RA, Galimberti M, Polchi P, Angelucci E, Baronciani D et al. Marrow transplantation for patients with thalassemia: Results in class 3 patients. Blood 1996; 87: 2082-2088
14. Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C et al. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol 2008; 143: 548-551
15. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-Thalassemia. Biol Blood Marrow Transplant 2003; 9: 519-528
16. Horan JT, Liesveld JL, Fenton P, Blumberg N, Walters MC. Hematopoietic stem cell transplantation for multiply transfused patients with sickle cell disease and thalassemia after low-dose total body irradiation, fludarabine, and rabbit antithymocyte globulin. Bone Marrow Transplant 2005; 35: 171-177
17. Gaziev J, Nguyen L, Puozzo C, Mozzi AF, Casella M, Perrone Donnorso M et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: A prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 2010; 115: 4597-4604
18. Danylesko I, Shimoni A, Nagler A. Treosulfan-based conditioning before hematopoietic SCT: More than a BU look-Alike. Bone Marrow Transplant 2012; 47: 5-14
19. Hilger RA, Harstrick A, Eberhardt W, Oberhoff C, Skorzec M, Baumgart J et al. Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer Chemother Pharmacol 1998; 42: 99-104
20. Glowka FK, Karazniewicz-Lada M, Grund G, Wrobel T, Wachowiak J. Pharmacokinetics of high-dose i.v. treosulfan in children undergoing treosulfanbased preparative regimen for allogeneic haematopoietic SCT. Bone Marrow Transplant 2008; 42: S67-S70
21. Scheulen ME, Hilger RA, Oberhoff C, Casper J, Freund M, Josten KM et al. Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clin Cancer Res 2000; 6: 4209-4216
22. Cappelli B, Chiesa R, Evangelio C, Biffi A, Roccia T, Frugnoli I et al. Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan. Br J Haematol 2009; 147: 554-560
23. Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E, Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404
24. De Witte T. The role of iron in patients after bone marrow transplantation. Blood Rev 2008; 22: S22-S28
25. Mathews V, George B, Viswabandya A, Abraham A, Ahmed R, Ganapule A et al. Improved clinical outcomes of high risk beta thalassemia major patients undergoing a HLA matched related allogeneic stem cell transplant with a treosulfan based conditioning regimen and peripheral blood stem cell grafts. PLoS One 2013; 8: E61637
26. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M et al. Glutathione S-Transferase M1 polymorphism: A risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004; 104: 1574-1577
27. Chandy M, Balasubramanian P, Ramachandran SV, Mathews V, George B, Dennison D et al. Randomized trial of two different conditioning regimens for bone marrow transplantation in thalassemia-The role of busulfan pharmacokinetics in determining outcome. Bone Marrow Transplant 2005; 36: 839-845
28. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: Results of a reduced-Toxicity conditioning regimen based on the use of treosulfan. Blood 2012; 120: 473-476
29. Choudhary D, Sharma SK, Gupta N, Kharya G, Pavecha P, Handoo A et al. Treosulfan-Thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: A single-center experience from north India. Biol Blood Marrow Transplant 2012; 19: 492-495
30. Rajasekar R, Mathews V, Lakshmi KM, George B, Viswabandya A, Chandy M et al. Cellular immune reconstitution and its impact on clinical outcome in children with beta thalassemia major undergoing a matched related myeloablative allogeneic bone marrow transplant. Biol Blood Marrow Transplant 2009; 15: 597-609
31. Iravani M, Tavakoli E, Babaie MH, Ashouri A, Khatami F, Ghavamzadeh A. Comparison of peripheral blood stem cell transplant with bone marrow transplant in class 3 thalassemic patients. Exp Clin Transplant 2010; 8: 66-73
32. Ghavamzadeh A, Iravani M, Ashouri A, Mousavi SA, Mahdavi N, Shamshiri A et al. Peripheral blood versus bone marrow as a source of hematopoietic stem cells for allogeneic transplantation in children with class I and II beta thalassemia major. Biol Blood Marrow Transplant 2008; 14: 301-308
33. Li C, Wu X, Feng X, He Y, Liu H, Pei F et al. A novel conditioning regimen improves outcomes in beta-Thalassemia major patients using unrelated donor peripheral blood stem cell transplantation. Blood 2012; 120: 3875-3881.